New Zealand has become one of the first countries to authorize the use of MDMA, commonly known as ecstasy, for therapeutic purposes. The decision allows trained therapists to administer MDMA-assisted psychotherapy to patients suffering from severe trauma, such as post-traumatic stress disorder (PTSD). The move follows successful clinical trials demonstrating MDMA’s potential to enhance therapy and facilitate emotional processing. Regulations will be strictly enforced, with treatment available only through authorized practitioners. This groundbreaking approval reflects a growing global reconsideration of psychedelic-assisted therapies. Authorities hope this innovative approach will offer relief to individuals for whom traditional treatments have proven ineffective, providing a new pathway to healing. The treatment is expected to become available in 2024.